News After FDA snub, DBV charts a new course for Viaskin peanut It’s been more than three years since DBV Technologies’ peanuty allergy therapy was
News NICE backs Aimmune's peanut allergy drug Palforzia for child... Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla
News DBV craters on FDA’s peanut allergy immunotherapy rejection DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
